Ward: Personal Finance

Loading...

Happy 75% Chaos 10% Sad 0% Well 80% Anger 0% Fear 0% Surprise 20%

0

SOXL: How Disciplined Tactical Moves In And Out Could Compound Wealth Over 30 Years

Happy 50% Chaos 20% Sad 10% Well 70% Anger 10% Fear 30% Surprise 20%

0

Risk Management For Retirees: When To Reduce Exposure

Happy 75% Chaos 20% Sad 5% Well 80% Anger 10% Fear 5% Surprise 30%

0

Elevance Health: Making The Bull Case For Ongoing Recovery (Rating Upgrade)

Happy 50% Chaos 20% Sad 10% Well 30% Anger 15% Fear 5% Surprise 25%

0

Impax Asset Management Group Plc (IPXAF) Q2 2026 Earnings Call Transcript

Happy 70% Chaos 10% Sad 5% Well 20% Anger 10% Fear 5% Surprise 30%

0

IDMO Vs. EFA: Momentum Investing Shows Great Track Record Thus A Strong Buy

Happy 30% Chaos 10% Sad 5% Well 20% Anger 10% Fear 5% Surprise 80%

0

Record Extremes, Alternative Investments, And The Hippo

Happy 30% Chaos 10% Sad 5% Well 60% Anger 20% Fear 10% Surprise 15%

0

My Income Portfolio - Looking For Dividends

Happy 80% Chaos 20% Sad 10% Well 70% Anger 10% Fear 5% Surprise 30%

0

Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript

Happy 20% Chaos 30% Sad 40% Well 10% Anger 60% Fear 50% Surprise 30%

0

I Wouldn't Dare Buy These 3 Popular Retirement-Wrecker Yield Traps

Happy 20% Chaos 30% Sad 10% Well 10% Anger 50% Fear 40% Surprise 30%

0

GE HealthCare Technologies: Doing Some Bottom Fishing

Happy 60% Chaos 20% Sad 10% Well 40% Anger 10% Fear 5% Surprise 30%

0

AMG Boston Common Global Impact Fund Q1 2026 Commentary

Happy 70% Chaos 20% Sad 10% Well 50% Anger 10% Fear 5% Surprise 30%

0

Root Inc.: Is This AI-Driven Insurer Finally Taking Root?

Happy 20% Chaos 30% Sad 10% Well 5% Anger 60% Fear 40% Surprise 30%

0

ORR: A Long/Short Hedge Fund Disguised As An ETF

Happy 50% Chaos 20% Sad 10% Well 70% Anger 10% Fear 10% Surprise 30%

0

CIO Weekly: In Search Of Breadth

Happy 50% Chaos 60% Sad 40% Well 30% Anger 70% Fear 50% Surprise 40%

0

Grace Therapeutics: Assessing The Path Forward For GTx-104

Happy 20% Chaos 10% Sad 5% Well 10% Anger 15% Fear 10% Surprise 30%

0

Harmonic: Gains From The Transition May Be Priced In

Happy 20% Chaos 10% Sad 5% Well 10% Anger 0% Fear 5% Surprise 10%

0

Hinde Group Q1 2026 Partner Letter

Happy 80% Chaos 20% Sad 0% Well 90% Anger 0% Fear 0% Surprise 30%

0

Akeso To Boost Manufacturing Of Cancer Drug

Akeso CFO Bing Wang says the Chinese biotech firm is investing “significantly” to expand manufacturing of its lung cancer drug as it anticipates growing demand in China and the US. He speaks exclusively to Bloomberg after Akeso presented positive results for the drug at the American Society of Clini…

← Prev